RTP Mobile Logo
Oncology Today with Dr Neil Love: Updates from the 2021 ASH Meeting on Chronic Lymphocytic Leukemia (Audio Interview)
Released February 2022

Featuring an interview with Dr Matthew Davids. Published February 2, 2022. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

    LEARNING OBJECTIVES

    • Individualize the selection of systemic therapy for newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings and the patient’s clinical presentation, biomarker profile, coexisting medical conditions and personal preferences.
    • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to evaluate and select available front-line options.
    • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
    • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
    • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy in patients with newly diagnosed CLL.
    • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory CLL.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
    • Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and appropriately refer eligible patients for clinical trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Matthew S Davids, MD, MMSc
    Associate Professor of Medicine
    Harvard Medical School
    Director of Clinical Research
    Division of Lymphoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: February 2022
    Expiration date: February 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):